CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DMK Pharmaceuticals Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DMK Pharmaceuticals Corp
11682 El Camino Real, Suite 300
Phone: (858) 997-2400p:858 997-2400 SAN DIEGO, CA  92130  United States Ticker: DMKPQDMKPQ
Filed for Bankruptcy on 2/2/2024
Case #24-10153, filed in the U.S. Bankruptcy Court for the District of Delaware
This entity represents the bankrupt estate of the former businesses (assets) of DMK Pharmaceuticals Corp that were not sold to zmi pharma inc. on 5/16/2024
Business Summary
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYesYes-Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Restructuring Officer Seth A.Cohen 61 6/27/2024 10/16/2023

Subsidiaries
Business Name Address City State/Province Country
US Compounding, Inc. 1270 Don's Lane Conway AR United States

Business Names
Business Name
Adamis Corporation
ADMP
Biosyn, Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 11 (As of 12/31/2022)
Outstanding Shares: 10,102,050 (As of 11/13/2023)
Shareholders: 82
Stock Exchange: OTC
Federal Tax Id: 820429727
Fax Number: (302) 636-5454
Email Address: webmaster@cellegy.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025